Strategic transactions and agreements - Zentalis Pharmaceuticals (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Oct. 25, 2025	Jan. 05, 2024	Dec. 31, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock				$ 221
Zentalis Asset Purchase Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock			$ 20,990
Number of shares issued	1,805,502
Common stock issued	$ 21,000
Share Price	$ 12.11
Percentage of discount related to unregistered share restrictions to be deducted from the share price	4.00%
Cash upon the achievement of a developmental milestone	$ 5,000		5,000
License agreement with Zentalis Pharmaceuticals, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License Agreement, Upfront Payment in Cash		$ 15,000
Shares issued		2,298,586
Issuance of common stock		$ 23,400	$ 23,388
Share Price		$ 11.12
Percentage of discount related to unregistered share restrictions to be deducted from the share price		8.50%
Transaction cost		$ 200